英基 IMGN 深 滬
已收盤 02-12 16:00:00 美东时间
31.23
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 31.23
- 總市值 77.76亿
- 52周最高 31.25
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.605
- 委 比 0.00%
- 總股本 2.49亿
- 歷史最高 31.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.51
- 每 手 1
- 風險率 6.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A Closer Look at AbbVie's Options Market Dynamics
Whales with a lot of money to spend have taken a noticeably bullish stance on A...
10-01 04:01
Decoding AbbVie's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE: ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
09-27 04:02
石英纤维布专家交流
（来源：老司机驾新车） 1、石英纤维布行业供需现状 供需关系与产能限制：当前石英纤维布行业需求大于供给，尽管近半年市场炒作较热，但实际供给量有限。产能受限主因工...
08-31 21:13
AbbVie’s IMGN151 Study: A New Hope for Recurrent Gynecological Cancers
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is...
08-25 00:37
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio授予了新任CEO Kristin Yarema 436,080股股票期权和153,505股限制性股票单位，作为其加入公司的激励。这些奖项包括四年归属期和基于 Nasdaq规则的条件。ImageneBio专注于免疫和炎症疾病治疗的开发。
08-01 20:15
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Ikena Oncology and Inmagene Biopharmaceuticals completed their merger, with the combined company renaming to ImageneBio (ticker: IMA) and trading on Nasdaq. Ikena executed a 1-for-12 reverse stock split, reducing shares from ~48.2M to ~4M, effective late July. Inmagene focuses on immunological/inflammatory diseases, with IMG-007 showing promise in clinical trials. Ikena specializes in cancer therapies. The merger and financing are expected to clo...
07-15 20:15
艾伯维挥起拳头
转自：新康界 艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！ 自免领域并购提速、神经科学重金押注、ADC赛道连出重拳，艾伯维以一场战略大突...
05-25 10:59
华东医药一季报彰显韧性，扣非归母净利润达历史同期最好水平
国内头部药企的创新转型正进入成果收获期。 近日，医药大白马华东医药（000963.SZ）发布2025年第一季度业绩报告。报告显示，2025年第一季度内公司实现营...
05-06 10:33
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
04-29 03:27
